156 related articles for article (PubMed ID: 21691915)
1. Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysis.
Bizzotto R; Zamuner S; Mezzalana E; De Nicolao G; Gomeni R; Hooker AC; Karlsson MO
AAPS J; 2011 Sep; 13(3):445-63. PubMed ID: 21691915
[TBL] [Abstract][Full Text] [Related]
2. Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients.
Bizzotto R; Zamuner S; De Nicolao G; Karlsson MO; Gomeni R
J Pharmacokinet Pharmacodyn; 2010 Apr; 37(2):137-55. PubMed ID: 20052524
[TBL] [Abstract][Full Text] [Related]
3. Analysis of variability in length of sleep state bouts reveals memory-free sleep subcomponents consistent among primary insomnia patients.
Bizzotto R; Zamuner S
J Neurophysiol; 2018 May; 119(5):1836-1851. PubMed ID: 29384456
[TBL] [Abstract][Full Text] [Related]
4. Sleep architecture and its relationship to insomnia.
Erman MK
J Clin Psychiatry; 2001; 62 Suppl 10():9-17. PubMed ID: 11388592
[TBL] [Abstract][Full Text] [Related]
5. A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep.
Karlsson MO; Schoemaker RC; Kemp B; Cohen AF; van Gerven JM; Tuk B; Peck CC; Danhof M
Clin Pharmacol Ther; 2000 Aug; 68(2):175-88. PubMed ID: 10976549
[TBL] [Abstract][Full Text] [Related]
6. Modeling sleep data for a new drug in development using markov mixed-effects models.
Kjellsson MC; Ouellet D; Corrigan B; Karlsson MO
Pharm Res; 2011 Oct; 28(10):2610-27. PubMed ID: 21681607
[TBL] [Abstract][Full Text] [Related]
7. Sleep Stage Transition Dynamics Reveal Specific Stage 2 Vulnerability in Insomnia.
Wei Y; Colombo MA; Ramautar JR; Blanken TF; van der Werf YD; Spiegelhalder K; Feige B; Riemann D; Van Someren EJW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934523
[TBL] [Abstract][Full Text] [Related]
8. Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model.
Steven Ernest C; Nyberg J; Karlsson MO; Hooker AC
J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):639-54. PubMed ID: 25308776
[TBL] [Abstract][Full Text] [Related]
9. CAP variables and arousals as sleep electroencephalogram markers for primary insomnia.
Terzano MG; Parrino L; Spaggiari MC; Palomba V; Rossi M; Smerieri A
Clin Neurophysiol; 2003 Sep; 114(9):1715-23. PubMed ID: 12948801
[TBL] [Abstract][Full Text] [Related]
10. Effects of zolpidem on cyclic alternating pattern, an objective marker of sleep instability, in Japanese patients with psychophysiological insomnia: a randomized crossover comparative study with placebo.
Ozone M; Yagi T; Itoh H; Tamura Y; Inoue Y; Uchimura N; Sasaki M; Shimizu T; Terzano MG; Parrino L
Pharmacopsychiatry; 2008 May; 41(3):106-14. PubMed ID: 18484552
[TBL] [Abstract][Full Text] [Related]
11. Insomnia and depression--sleep EEG changes.
Idzikowski C
J Psychosom Res; 1994; 38 Suppl 1():27-40. PubMed ID: 7799248
[No Abstract] [Full Text] [Related]
12. Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods.
Saletu B; Saletu-Zyhlarz G; Anderer P; Brandstätter N; Frey R; Gruber G; Klösch G; Mandl M; Grünberger J; Linzmayer L
Neuropsychobiology; 1997; 36(3):130-52. PubMed ID: 9313245
[TBL] [Abstract][Full Text] [Related]
13. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
[TBL] [Abstract][Full Text] [Related]
14. Actigraphy and insomnia: a closer look. Part 1.
Chambers MJ
Sleep; 1994 Aug; 17(5):405-8; discussion 408-10. PubMed ID: 7880249
[TBL] [Abstract][Full Text] [Related]
15. Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia.
Lundahl J; Staner L; Staner C; Loft H; Deacon S
Psychopharmacology (Berl); 2007 Nov; 195(1):139-46. PubMed ID: 17653697
[TBL] [Abstract][Full Text] [Related]
16. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial.
Morin CM; Koetter U; Bastien C; Ware JC; Wooten V
Sleep; 2005 Nov; 28(11):1465-71. PubMed ID: 16335333
[TBL] [Abstract][Full Text] [Related]
17. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.
Bes F; Hofman W; Schuur J; Van Boxtel C
Neuropsychobiology; 1992; 26(4):193-7. PubMed ID: 1299794
[TBL] [Abstract][Full Text] [Related]
18. Multivariate analysis of full-term neonatal polysomnographic data.
Gerla V; Paul K; Lhotska L; Krajca V
IEEE Trans Inf Technol Biomed; 2009 Jan; 13(1):104-10. PubMed ID: 19129029
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of ramelteon in a double-blind, placebo-controlled, crossover study in Japanese patients with chronic primary insomnia.
Kohsaka M; Kanemura T; Taniguchi M; Kuwahara H; Mikami A; Kamikawa K; Uno H; Ogawa A; Murasaki M; Sugita Y
Expert Rev Neurother; 2011 Oct; 11(10):1389-97. PubMed ID: 21955196
[TBL] [Abstract][Full Text] [Related]
20. Subjective and psychophysiologic insomnia: an examination of sleep tendency and personality.
Dorsey CM; Bootzin RR
Biol Psychiatry; 1997 Jan; 41(2):209-16. PubMed ID: 9018392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
